These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

105 related items for PubMed ID: 1453564

  • 21. Fluorine-18-FDG PET in Paget's disease of bone.
    Cook GJ, Maisey MN, Fogelman I.
    J Nucl Med; 1997 Sep; 38(9):1495-7. PubMed ID: 9293817
    [Abstract] [Full Text] [Related]

  • 22. Identification of early recurrence of primary central nervous system tumors by [18F]fluorodeoxyglucose positron emission tomography.
    Glantz MJ, Hoffman JM, Coleman RE, Friedman AH, Hanson MW, Burger PC, Herndon JE, Meisler WJ, Schold SC.
    Ann Neurol; 1991 Apr; 29(4):347-55. PubMed ID: 1929205
    [Abstract] [Full Text] [Related]

  • 23. Comparison of [11C]flumazenil and [18F]FDG as PET markers of epileptic foci.
    Savic I, Ingvar M, Stone-Elander S.
    J Neurol Neurosurg Psychiatry; 1993 Jun; 56(6):615-21. PubMed ID: 8509773
    [Abstract] [Full Text] [Related]

  • 24. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation.
    Wahl RL, Zasadny K, Helvie M, Hutchins GD, Weber B, Cody R.
    J Clin Oncol; 1993 Nov; 11(11):2101-11. PubMed ID: 8229124
    [Abstract] [Full Text] [Related]

  • 25. Imaging local brain function with emission computed tomography.
    Kuhl DE.
    Radiology; 1984 Mar; 150(3):625-31. PubMed ID: 6607481
    [Abstract] [Full Text] [Related]

  • 26. Comparison of fluorine-18-fluorodeoxyglucose and carbon-11-methionine PET in detection of malignant tumors.
    Inoue T, Kim EE, Wong FC, Yang DJ, Bassa P, Wong WH, Korkmaz M, Tansey W, Hicks K, Podoloff DA.
    J Nucl Med; 1996 Sep; 37(9):1472-6. PubMed ID: 8790196
    [Abstract] [Full Text] [Related]

  • 27. [Analysis of glucose metabolism in patients with esophageal cancer by PET: estimation of hexokinase activity in the tumor and usefulness for clinical assessment using 18F-fluorodeoxyglucose].
    Fukunaga T, Enomoto K, Okazumi S, Kikuchi T, Yamamoto H, Koide Y, Isono K.
    Nihon Geka Gakkai Zasshi; 1994 May; 95(5):317-25. PubMed ID: 8007937
    [Abstract] [Full Text] [Related]

  • 28. [18F]fluorodeoxyglucose uptake in tumors: kinetic vs. steady-state methods with reference to plasma insulin.
    Minn H, Leskinen-Kallio S, Lindholm P, Bergman J, Ruotsalainen U, Teräs M, Haaparanta M.
    J Comput Assist Tomogr; 1993 May; 17(1):115-23. PubMed ID: 8419418
    [Abstract] [Full Text] [Related]

  • 29. [Cerebral glucose metabolism in dementia (PET-FDG study)].
    Hatazawa J, Itoh M, Matsuzawa T.
    Rinsho Hoshasen; 1989 Oct; 34(11):1343-8. PubMed ID: 2601096
    [Abstract] [Full Text] [Related]

  • 30. Comparison of fluorine-18-fluorodeoxyglucose PET, MRI and endoscopy for staging head and neck squamous-cell carcinomas.
    Laubenbacher C, Saumweber D, Wagner-Manslau C, Kau RJ, Herz M, Avril N, Ziegler S, Kruschke C, Arnold W, Schwaiger M.
    J Nucl Med; 1995 Oct; 36(10):1747-57. PubMed ID: 7562038
    [Abstract] [Full Text] [Related]

  • 31. Monitoring liver tumor therapy with [18F]FDG positron emission tomography.
    Nagata Y, Yamamoto K, Hiraoka M, Abe M, Takahashi M, Akuta K, Nishimura Y, Jo S, Masunaga S, Kubo S.
    J Comput Assist Tomogr; 1990 Oct; 14(3):370-4. PubMed ID: 2335602
    [Abstract] [Full Text] [Related]

  • 32. [18F]FDG PET in fatal familial insomnia: the functional effects of thalamic lesions.
    Perani D, Cortelli P, Lucignani G, Montagna P, Tinuper P, Gallassi R, Gambetti P, Lenzi GL, Lugaresi E, Fazio F.
    Neurology; 1993 Dec; 43(12):2565-9. PubMed ID: 8255458
    [Abstract] [Full Text] [Related]

  • 33. Measurement of cerebral glucose metabolic rates in the anesthetized rat by dynamic scanning with 18F-FDG, the ATLAS small animal PET scanner, and arterial blood sampling.
    Shimoji K, Ravasi L, Schmidt K, Soto-Montenegro ML, Esaki T, Seidel J, Jagoda E, Sokoloff L, Green MV, Eckelman WC.
    J Nucl Med; 2004 Apr; 45(4):665-72. PubMed ID: 15073264
    [Abstract] [Full Text] [Related]

  • 34. Measurement of regional cerebral glucose utilization with fluorine-18-FDG and PET in heterogeneous tissues: theoretical considerations and practical procedure.
    Lucignani G, Schmidt KC, Moresco RM, Striano G, Colombo F, Sokoloff L, Fazio F.
    J Nucl Med; 1993 Mar; 34(3):360-9. PubMed ID: 8441024
    [Abstract] [Full Text] [Related]

  • 35. Fluorine-18-fluorodeoxyglucose PET to determine regional cerebral glucose utilization: a re-examination.
    Schmidt KC, Lucignani G, Sokoloff L.
    J Nucl Med; 1996 Feb; 37(2):394-9. PubMed ID: 8667082
    [No Abstract] [Full Text] [Related]

  • 36. [Cancer screening with whole-body FDG PET].
    Yasuda S, Ide M, Takagi S, Shohtsu A.
    Kaku Igaku; 1996 Oct; 33(10):1065-71. PubMed ID: 8952258
    [Abstract] [Full Text] [Related]

  • 37. [F-18 FDG PET in dementia].
    Ichiya Y.
    Rinsho Hoshasen; 1989 Oct; 34(11):1337-41. PubMed ID: 2601095
    [Abstract] [Full Text] [Related]

  • 38. Expression of glucose transporters in human pancreatic tumors compared with increased FDG accumulation in PET study.
    Higashi T, Tamaki N, Honda T, Torizuka T, Kimura T, Inokuma T, Ohshio G, Hosotani R, Imamura M, Konishi J.
    J Nucl Med; 1997 Sep; 38(9):1337-44. PubMed ID: 9293783
    [Abstract] [Full Text] [Related]

  • 39. Effect of nicotinic acid on exogenous myocardial glucose utilization.
    Stone CK, Holden JE, Stanley W, Perlman SB.
    J Nucl Med; 1995 Jun; 36(6):996-1002. PubMed ID: 7769458
    [Abstract] [Full Text] [Related]

  • 40. Investigations of cerebral glucose utilization into the newborn brain: a [18F]-FDG positron emission tomography study using a high resolution multiwire proportional chamber detector device.
    Bauer R, Bergmann R, Beyer GJ, Manfrass P, Steinbach J, Kretzschmar M, Enghardt W, Hoyer D, Günther K, Schubert H.
    Exp Pathol; 1991 Jun; 42(4):229-33. PubMed ID: 1959583
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.